-
Mashup Score: 2Tech-Enabled Power To The People: Ingratiating Chatbots and a Virtuous Food App - TimmermanReport.com - 18 hour(s) ago
For at least a decade, nearly every tech company has promoted their product as facilitating the “democratization” of something – perhaps “data driven medicine,” or “genetic information” or “access to clinical trials” or “digital health” (all real examples). Like “mission-driven,” “results-oriented,” and “disruptive,” the term “democratization” has become so overused by the tech community that… Read More
Source: timmermanreport.comCategories: General Medicine NewsTweet
-
Mashup Score: 3Our Collective Hope For AI in Health, Plus Explanatory Models and an Epic Podcast - TimmermanReport.com - 2 day(s) ago
A recent piece by Nathan Price captures our collective hope for AI in health with unusual clarity, even as there remains impassioned disagreement regarding how close these ambitions are to meaningful realization. For context, Price is Professor and Co-Director of the Center for Human Healthspan at the Buck Institute for Research on Aging and… Read More
Source: timmermanreport.comCategories: General Medicine NewsTweet-
Latest @timmermanreport looks @ common themes uniting our collective aspirations 4 AI in geroscience, wellness, nutrition, R&D; asks how far r we from realizing these loft ambitions (estimates vary). Plus Explanatory Models, Epic podcast. https://t.co/4KHMOmZw5a @NathanPriceSci
-
-
Mashup Score: 0
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Source: timmermanreport.comCategories: General Medicine NewsTweet-
Can you improve your health without obsessing about it? My latest @timmermanreport https://t.co/Sifl9l8A8b . #longevity @wellness @fittinsider @DrMJoyner @hjluks
-
-
Mashup Score: 0
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Source: timmermanreport.comCategories: General Medicine NewsTweet-
Can you improve your health without obsessing about it? My latest @timmermanreport https://t.co/Sifl9l8A8b . #longevity @wellness @fittinsider @DrMJoyner @hjluks
-
-
Mashup Score: 0
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Source: timmermanreport.comCategories: General Medicine NewsTweet-
Can you improve your health without obsessing about it? My latest @timmermanreport https://t.co/Sifl9l8A8b . #longevity @wellness @fittinsider @DrMJoyner @hjluks
-
-
Mashup Score: 1
(Guest) Editor Note: Martin Gaynor, the Lester A. Hamburg University Professor of Economics and Public Policy at Carnegie Mellon University, was recently honored with the Victor R. Fuchs Award for Lifetime Contributions to the Field of Health Economics by the American Society of Health Economists. His response (shared with his permission) was both striking and… Read More
Source: timmermanreport.comCategories: General Medicine NewsTweet-
Just out in @timmermanreport - thought-provoking reflections from distinguished health economist Martin Gaynor on the striking non-linearity of his career path https://t.co/fbtTIhIyFB I love this stuff (see: https://t.co/6tPz6N2hA0, https://t.co/AdGmxz2GgM) cc @CassSunstein https://t.co/9N9aF65Zcx
-
-
Mashup Score: 1
(Guest) Editor Note: Martin Gaynor, the Lester A. Hamburg University Professor of Economics and Public Policy at Carnegie Mellon University, was recently honored with the Victor R. Fuchs Award for Lifetime Contributions to the Field of Health Economics by the American Society of Health Economists. His response (shared with his permission) was both striking and… Read More
Source: timmermanreport.comCategories: General Medicine NewsTweet-
Just out in @timmermanreport - thought-provoking reflections from distinguished health economist Martin Gaynor on the striking non-linearity of his career path https://t.co/fbtTIhIyFB I love this stuff (see: https://t.co/6tPz6N2hA0, https://t.co/AdGmxz2GgM) cc @CassSunstein https://t.co/9N9aF65Zcx
-
-
Mashup Score: 3The Four Dysfunctions of Corporate Cultures—Applied to Biopharma - TimmermanReport.com - 13 day(s) ago
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Source: timmermanreport.comCategories: General Medicine NewsTweet-
Greetings from @timmermanreport, which I'm covering while @ldtimmerman traversing in Himalayas & raising money for worthy biomedical causes. Out today: insightful (as usual) piece by Dr. @AlexHarding7 on Four Dysfunctions of Corporate (Biotech) Culture: https://t.co/sP53aFv7rF
-
-
Mashup Score: 1
The arrival of generative AI prompted many to worry about the adverse impact on human agency; after all, if the technology can effectively do what we’re doing, where does that leave us? This concern was the central focus of Reid Hoffman’s “Superagency,” which I reviewed for the WSJ earlier this year – see here. Essentially,… Read More
Source: timmermanreport.comCategories: General Medicine NewsTweet-
A key challenge was modulating eating since as you know, used to be almost impossible to durably sustain weight loss in obesogenic environment. I’m optimistic (that word again!), as I wrote (https://t.co/sBdRpYsNIw) about GLP1’s unleashing agentic dividend here… @DanielJDrucker https://t.co/cGFu7WjWHE
-
-
Mashup Score: 4You Have Chosen … Poorly: Why Drug Developers Make Bad Decisions - TimmermanReport.com - 16 day(s) ago
Drug development remains an incredibly expensive endeavor. Much of the cost can be attributed to late-stage clinical trial failures. The burden is borne first and foremost by clinical trial participants who aren’t helped by the experimental medicine. It also significantly impacts the companies sponsoring these studies. Everyone would like to improve the chances that a… Read More
Source: timmermanreport.comCategories: General Medicine NewsTweet-
Exactly this sort of poor decision making discussed here: https://t.co/30LjubP2Ln w characteristically penetrating insights from @sciencescanner (and others)… https://t.co/iQ6FYVP9Uj
-
Just posted - new @timmermanreport piece about how ingratiating chatbots and a virtuous food app are potent examples of democratization of technology - perhaps (but not inevitably) for the better. https://t.co/tgr9SSKUnw cc @zakkohane @goldbergcarey @peteratmsr